ALLEGAN — Perrigo Co. (NASDAQ: PRGO) announced that the United States District Court for the Western District of Michigan has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex tablets.
Perrigo had been sued by Adams Respiratory Therapeutics Inc., a subsidiary of Reckitt Benckiser Group plc, the New Drug Application holder and patent owner. The court ruled that the Perrigo product did not infringe the patent in suit. Perrigo received FDA approval in December 2011 and expects to launch the product within 90 days.
Mucinex (Guaifenesin Extended-Release Tablets, 600 mg), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $146 million through food, drug and mass merchandisers for the last 12 months, as measured by Information Resources Inc.
Perrigo’s Chairman and CEO Joseph C. Papa stated, “This is another example of Perrigo’s significant investment and commitment to bringing new store brand products to the market. Perrigo saves consumers over $5 billion annually and continually strives to make quality healthcare more affordable.”
Perrigo develops, manufactures and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The company’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. More at www.perrigo.com.